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Summary
A	total	of	1,561	pigs	(initially	4	d	of	age)	were	used	to	determine	the	effects	of	a	porcine	
reproductive	and	respiratory	syndrome	virus	(PRRSv)	subunit	vaccine,	PRRSV-RS	
(Sirrah-Bios,	Ames,	IA),	on	mortality	rate	and	finisher	pig	growth	performance	in	a	
PRRSv-positive	commercial	herd.	Pigs	were	randomly	assigned	by	litter	to	either	the	
subunit	PRRSv	vaccine	or	non-vaccinated	control	group.	Pigs	in	the	vaccinated	group	
received	an	intramuscular	injection	of	1	mL	PRRSV-RS	vaccine	at	processing	(approxi-
mately	4	d	after	birth)	and	again	at	weaning	(approximately	24	d	of	age).	Vaccinated	
and	control	pigs	were	comingled	in	a	single	nursery	during	the	nursery	phase.	In	the	
finishing	phase,	pigs	were	housed	in	a	standard	commercial	curtain-sided	finisher	barn	
by	treatment	and	gender	by	pen,	with	treatments	randomly	distributed	across	pens.	
Mortality	was	tracked	from	processing	(4	d	of	age)	to	market	(d	187	to	193).	There	was	
no	difference	between	the	control	and	vaccinated	pigs	for	cumulative	mortality	(21.5%	
vs.	20.6%,	P =	0.67)	or	for	mortality	during	each	production	phase	(processing	to	wean-
ing:	9.5%	vs.	7.1%,	P	=	0.08;	nursery:	9.3%	vs.	9.2%,	P	=	0.95;	finishing:	4.4%	vs.	5.9%,	
P	=	0.20).	Pigs	were	initially	weighed	by	single-sex	pens	(control	or	vaccinated)	2	wk	
after	placement	into	the	finisher	(d	0),	and	at	that	time,	control	and	vaccinated	mean	
pig	weights	were	not	different	(58.4	vs.	58.7	lb,	P =	0.90).	Pens	of	pigs	were	subse-
quently	weighed	every	2	wk,	and	feed	consumption	was	recorded	to	calculate	ADG,	
ADFI,	and	F/G.	Overall	(d	0	to	112),	control	and	vaccinated	pig	performance	was	
similar	(ADG:	1.96	vs.	1.93	lb,	P =	0.45;	ADFI:	5.35	vs.	5.36	lb,	P =	0.94;	F/G:	2.74	
vs.	2.78,	P =	0.15)	throughout	the	finishing	period.	This	resulted	in	no	difference	
(P =	0.79)	in	off-test	(d	112)	weights	between	control	(271.9	lb)	and	vaccinated	
(270.4	lb)	pigs.	These	data	indicate	that	this	subunit	PRRSv	vaccine	did	not	affect	
finisher	pig	performance	or	mortality	in	this	commercial	herd.	
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Introduction
Porcine	reproductive	and	respiratory	syndrome	is	caused	by	a	virus	in	the	family	Arteri-
viridae.	This	virus	has	become	endemic	in	many	herds.	Continual	evolution	of	porcine	
reproductive	and	respiratory	syndrome	virus	(PRRSv)	strains	has	made	development	
of	an	effective	and	reliable	vaccine	difficult.	Modified-live	and	whole	virus	inactivated	
PRRSv	vaccine	products	are	available	commercially.	Inactivated	products	have	not	
been	demonstrated	to	be	efficacious	under	field	conditions.	Use	of	the	modified-live	
vaccines	is	considered	to	provide	more	effective	immunity	than	inactivated	products.	
However,	the	modified-live	PRRSv	vaccine	is	shed	and	will	transmit	to	unvaccinated	
1	Appreciation	is	expressed	to	J-Six	Enterprises,	Seneca,	KS,	for	their	assistance	and	for	providing	the	pigs	
and	facilities	used	in	this	experiment.
2	Department	of	Diagnostic	Medicine/Pathobiology,	Kansas	State	University.
3	Abilene	Animal	Hospital,	PA,	Abilene,	KS.
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pigs.	Also,	there	is	concern	that	further	transmission	of	the	PRRSv	vaccine	strain	virus	
will	increase	the	potential	for	reversion	to	virulence.	
Another	class	of	PRRSv	vaccines	consists	of	subunit	vaccines.	Subunit	vaccines	are	
formed	by	using	specific	proteins	of	a	virus	to	which	an	antibody	response	is	stimulated.	
Thus,	like	a	whole	virus	inactivated	vaccine	product,	a	subunit	vaccine	cannot	propagate	
or	revert	to	virulence.	Commercially	available	subunit	vaccines	have	been	proven	to	
provide	effective	immunization	against	other	viruses,	such	as	porcine	circovirus		
type	2.	Recently,	a	new	subunit	PRRSv	vaccine,	PRRSV-RS	(Sirrah-Bios,	Ames,	IA),	
has	been	made	available	for	use	on	sows	or	growing	pigs.	This	vaccine	contains	an	
adjuvant	and	a	heterodimer	of	the	PRRSv	glycoprotein	5	and	matrix	protein	expressed	
with	an	AlphaVax	replicon	vector.	It	has	been	documented	in	a	mouse	model	that	a	
heterodimer	of	specific	proteins	is	necessary	to	promote	neutralizing	antibodies	against	
equine	arteritis	virus,	also	a	member	of	the	family	Arteriviridae.	For	that	reason,	it	has	
been	suggested	that	the	GP5-M	heterodimer	may	induce	cross-protective	neutralizing	
antibodies	against	PRRSv	infection	in	the	pig	and	potentially	allow	for	differentiat-
ing	capabilities	between	vaccinated	and	infected	pigs.	However,	there	is	limited	data	
demonstrating	subunit	PRRSv	vaccine	efficacy	under	field	conditions.	Thus,	the	objec-
tive	of	this	trial	was	to	evaluate	the	effects	of	a	subunit	PRRSv	vaccine	(PRRSV-RS)	
vaccine	on	cumulative	mortality	rate,	growth	performance,	and	feed	efficiency	of	
commercial	finisher	pigs.
Procedures
Procedures	used	in	this	trial	were	approved	by	the	Kansas	State	University	Institutional	
Animal	Care	and	Use	Committee.	
A	total	of	1,561	pigs	from	140	litters	within	a	single	week	of	farrowings	across	5	sow	
farms	were	assigned	to	either	a	non-vaccinated	control	or	subunit	PRRSv	vaccine	
treatment	group.	Treatment	groups	were	formed	by	randomly	assigning	the	first	litter	
processed	at	each	sow	farm	to	one	of	the	treatments	and	then	alternating	vaccine	treat-
ment	assignments	on	subsequently	processed	litters.	This	resulted	in	70	litters	repre-
sented	within	the	781	control	pigs	and	70	litters	represented	within	the	780	vaccinated	
pigs.	Pigs	in	the	vaccinated	group	received	1	mL	of	PRRSV-RS	vaccine	intramuscularly	
at	processing	(4	d	of	age)	and	again	at	weaning	(approximately	24	d	of	age).	All	pigs	
were	weaned	as	a	group	into	a	single	nursery.
Pigs	were	identified	by	ear	tags,	and	mortality	was	tracked	by	collecting	ear	tags	of	pigs	
that	died	or	were	humanely	euthanized.	Mortality	was	tracked	from	processing	to	
weaning,	weaning	to	the	end	of	the	nursery	period,	and	throughout	the	finishing	period	
until	the	majority	of	the	pigs	were	marketed.	Cumulative	mortality	was	determined	by	
identifying	the	number	of	pigs	in	each	treatment	group	that	died	or	were	euthanized	
from	processing	to	marketing	day	divided	by	the	initial	number	of	pigs	in	each	treat-
ment.
Throughout	the	nursery	period,	control	and	vaccinated	pigs	were	comingled	within	
single-sex	pens,	and	all	test	pigs	were	contained	within	a	common	room.	All	pigs	were	
vaccinated	with	a	2-dose	porcine	circovirus	type	2	vaccine	and	a	Mycoplasma hyopneu-
moniae	vaccine	during	the	nursery	period	according	to	routine	nursery	procedures.	
Similar	diets	were	fed	to	all	pigs	throughout	the	nursery	period.
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Pigs	were	moved	to	a	single	finisher	barn	and	separated	by	vaccine	treatment	(vacci-
nated	or	control)	and	gender	(barrow	or	gilt).	There	were	12	pens	of	each	treatment	×	
gender	combination,	with	the	exception	of	vaccinated	barrows,	for	which	there	were	
13	pens.	Pens	(10	×	18	ft)	for	each	treatment	were	randomly	distributed	throughout	
the	barn.	Each	pen	was	equipped	with	a	double	swinging	waterer	and	a	3-hole	dry	self-
feeder,	allowing	for	ad	libitum	access	to	water	and	feed.	An	automated	feeding	system	
(FeedPro;	Feedlogic	Corp.,	Willmar,	MN)	was	used	in	the	barn	to	deliver	and	measure	
feed	added	to	individual	pen	feeders.	Pigs	were	weighed	and	feed	intake	was	recorded	
beginning	2	wk	after	arrival	in	the	finisher	(d	0)	and	again	on	d	14,	28,	41,	56,	70,	
90,	and	112.	From	these	data,	ADG,	ADFI,	and	F/G	were	calculated.	On	d	90,	there	
were	0,	2,	or	4	heavy	pigs	removed	per	pen	in	a	balanced	manner	across	treatment	and	
gender,	resulting	in	84	“top”	pigs	marketed	per	vaccine	treatment.	At	the	end	of	the	
trial,	pigs	were	marketed	over	2	consecutive	days	in	a	balanced	fashion,	with	the	last	pigs	
being	weighed	off	test	on	d	112.	
Finisher	growth	and	feed	performance	data	were	analyzed	as	a	completely	randomized	
design	using	the	GLIMMIX	procedure	of	SAS	(SAS	Institute	Inc.,	Cary,	NC)	and	pen	
as	the	experimental	unit.	Vaccine	treatment	was	managed	as	the	main	fixed	effect	of	
interest;	however,	gender	was	added	in	the	model	to	control	for	expected	differences	
in	growth	rate	between	barrows	and	gilts.	Differences	between	treatments	were	deter-
mined	by	using	least	squares	means	(P < 0.05).	
Mortality	data	were	analyzed	using	the	FREQ	procedure	in	SAS.	Mortality	differences	
between	treatments	were	determined	using	the	chi-square	test	(P <	0.05).	Analysis	was	
performed	on	mortality	data	both	within	production	phase	(processing	to	weaning,	
nursery,	and	entry	to	finisher	to	off	test)	and	cumulatively.	
Results and Discussion
There	were	no	gender	×	vaccine	treatment	interactions	for	the	response	criteria	in	the	
finishing	trial.	Although	barrows	were	1	lb	lighter	(58.0	vs.	59.0	lb,	P =	0.90)	than	gilts	
initially,	growth	performance	across	genders	was	as	expected.	Barrows	had	greater	over-
all	ADG	(2.01	vs.	1.87	lb, P <	0.001)	and	ADFI	(5.65	vs.	5.07	lb,	P <	0.001)	and	poorer	
F/G	(2.81	vs.	2.70,	P <	0.001)	than	gilts.
Non-vaccinated	control	pigs	performed	similarly	to	vaccinated	pigs	during	the	finishing	
period	(Table	1).	When	pigs	were	first	weighed,	2	wk	after	entry	to	the	finisher,	there	
was	no	difference	(P =	0.90)	in	weight	between	controls	(58.4	lb)	and	vaccinates	
(58.7	lb).	From	this	point	forward,	there	was	no	difference	(P >	0.06)	in	ADG,	ADFI,	
or	F/G	between	the	2	treatment	groups.	This	lack	of	difference	in	performance	during	
the	finishing	period	resulted	in	similar	(P =	0.79)	off-test	(d	112)	weights	between	
controls	(271.9	lb)	and	vaccinates	(270.4	lb).
Mortality,	either	cumulative	or	within	production	phase,	was	not	different	(P >	0.08)	
between	treatment	groups	(Table	2).	Historically,	during	the	nursery	period,	pigs	in	
this	production	system	undergo	natural	exposure	to	PRRSv	and	influenza.	During	the	
nursery	period,	pigs	used	in	this	trial	exhibited	clinical	signs	indicating	similar	exposure	
to	PRRSv	and	influenza	virus.	The	lack	of	difference	in	growth	performance	detected	
in	this	trial	between	controls	and	vaccinates	indicates	that	the	vaccine	did	not	have	a	
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negative	or	positive	impact	on	growth	or	mortality.	This	is	important	because	it	appears	
that	the	majority	of	the	cost	associated	with	the	vaccine	would	be	due	to	administration	
materials,	labor,	and	the	vaccine	product	itself.	
Although	this	subunit	PRRSv	vaccine	is	made	from	viral	strains	similar	to	historical	
strains,	which	are	considered	to	provide	some	cross-protective	immunity,	it	is	unknown	
whether	the	vaccine-induced	level	of	protection	varies	with	viral	strain	challenge.	In	
this	herd,	which	has	historical	PRRSv-associated	challenge,	this	subunit	PRRSv	vaccine	
failed	to	influence	overall	mortality	or	growth	performance	during	the	finishing	phase.
Table 1. Effect of PRRSV-RS vaccine on growth performance of finisher pigs1
Treatment2
Item Control Vaccinated Probability, P <
Initial	wt,	lb 58.4	±	1.7 58.7	±	1.7 0.90
d	0	to	112
					ADG,	lb 1.96	±	0.03 1.93	±	0.03 0.45
					ADFI,	lb 5.35	±	0.08 5.36	±	0.08 0.94
					F/G 2.74	±	0.02 2.78	±	0.02 0.15
Final	wt,	lb 271.9	±	3.9 270.4	±	3.8 0.79
1	A	total	of	1,561	pigs	(barrows	or	gilts)	from	140	litters	across	5	sow	farms	were	assigned	to	1	of	2	treatments	
at	processing	(4	d	of	age)	by	randomly	assigning	entire	litters	to	either	the	vaccinated	or	non-vaccinated	control	
groups.	Control	and	vaccinated	pigs	were	comingled	in	the	nursery	and	then	separated	by	vaccine	treatment	and	
gender	in	the	finisher	barn.	Treatment	pens	were	randomly	distributed	throughout	the	barn.	There	were	24	pens	
of	control	pigs	and	25	pens	of	vaccinated	pigs.	All	pens	of	pigs	(1,292	pigs	total)	were	initially	weighed	2	wk	after	
placement	in	the	finisher	(d	0)	and	then	on	d	14,	28,	41,	56,	70,	90,	and	112.		
2	Treatments	were:	Control	=	no	vaccine	administered	and	Vaccinated	=	1	mL	PRRSV-RS	administered	intra-
muscularly	at	processing	and	weaning	(approximately	24	d	of	age).	Results	are	reported	as	least	squares	mean	±	
standard	error	of	the	mean.
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Table 2. Effect of PRRSV-RS vaccine on within-period and cumulative mortality1
Treatment2
Probability,	P <Item Control Vaccinate
Inventory
					Processing3 781 780 ---
					Weaning4 707 725 ---
					Entry	to	finisher5 641 658 ---
					Off	test6,7 529 535 ---
Within-period	mortality
					Processing	to	weaning,	% 9.5 7.1 0.08
					Nursery,	% 9.3 9.2 0.95
					Finisher,	% 4.4 5.9 0.20
Cumulative	mortality
					Processing	to	weaning,	% 9.5 7.1 0.08
					Processing	to	end	of	nursery,	% 17.9 15.6 0.23
					Processing	to	off	test,	%6 21.5 20.6 0.67
1	A	total	of	1,561	pigs	(barrows	or	gilts)	from	140	litters	across	5	sow	farms	were	assigned	to	1	of	2	treatments	
at	processing	(4	d	of	age)	by	randomly	assigning	entire	litters	to	either	the	vaccinated	or	non-vaccinated	control	
groups.	Control	and	vaccinated	pigs	were	comingled	in	the	nursery	and	then	separated	by	vaccine	treatment	and	
gender	in	the	finisher	barn.	Mortality	was	tracked	for	controls	and	vaccinates	from	processing	to	the	end	of	the	
finishing	portion	of	the	trial.
2	Treatments	were:	Control	=	no	vaccine	administered	and	Vaccinated	=	1	mL	PRRSV-RS	administered	intra-
muscularly	at	processing	and	weaning.	
3	4	d	of	age.	
4	Weaning	age	range	was	20	to	26	d	of	age.
5	Entry-to-finisher	age	range	was	60	to	66	d	of	age.
6	Off-test	age	range	was	187	to	193	d	of	age.
7	Inventory	at	off	test	(d	112)	excludes	pigs	marketed	(84	controls	and	84	vaccinates)	on	d	90	of	the	trial.
